Stockscreener 앱 받기
2.47%
전일 마감가:
$183.69
열려 있는:
$183.18
하루 거래량:
640.48K
Relative Volume:
0.77
시가총액:
$11.48B
수익:
$13.84B
순이익/손실:
$1.10B
주가수익비율:
17.16
EPS:
10.4185
순현금흐름:
$1.49B
1주 성능:
-21.42%
1개월 성능:
-23.04%
6개월 성능:
+24.18%
1년 성능:
+38.83%
1일 변동 폭
$178.81
$186.96
1주일 범위
$176.59
$208.53
52주 변동 폭
$101.00
$247.49
다비타 Stock (DVA) Company Profile
명칭
Davita Inc
전화
310-536-2668
주소
2000 16TH STREET, DENVER, CO
Compare DVA vs HCA, THC, FMS, EHC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
178.91 | 15.17B | 13.84B | 1.10B | 1.49B | 10.42 |
HCA
Hca Healthcare Inc
|
412.52 | 86.43B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
261.47 | 20.96B | 21.46B | 2.65B | 3.35B | 19.23 |
FMS
Fresenius Medical Care Ag Adr
|
23.95 | 13.36B | 22.44B | 1.35B | 2.03B | 1.9002 |
EHC
Encompass Health Corp
|
124.52 | 11.30B | 6.07B | 793.80M | 464.40M | 5.9914 |
다비타 Stock (DVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-06 | 개시 | Barclays | Equal Weight |
| 2023-08-07 | 업그레이드 | UBS | Neutral → Buy |
| 2022-11-01 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-10-31 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-08-19 | 재개 | UBS | Buy |
| 2022-06-21 | 재확인 | BofA Securities | Underperform |
| 2021-09-10 | 개시 | Cowen | Market Perform |
| 2021-08-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-03-26 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-10-25 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2019-09-11 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-01-08 | 업그레이드 | UBS | Sell → Neutral |
| 2019-01-03 | 개시 | Deutsche Bank | Buy |
| 2018-12-14 | 개시 | Barclays | Overweight |
| 2018-11-28 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-11-16 | 개시 | UBS | Sell |
| 2018-11-08 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2018-09-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-01-04 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-12 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2017-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2017-12-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2017-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-12-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
다비타 주식(DVA)의 최신 뉴스
DaVita Healthcare Partners stock hits all-time high at 239.72 USD - Investing.com Canada
DaVita Inc (DVA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DaVita Inc (DVA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DaVita Inc (DVA) Income Statement - TradingKey
DaVita Inc (DVA) Institutional Confidence - TradingKey
DVA|DaVita Inc|Price:236.300|Chg%:+0.860 - TradingKey
DaVita stock trades steadily as dialysis volumes support margins - Ad-hoc-news.de
DVA|DaVita Inc|Price:235.440|Chg%:+1.160 - TradingKey
DaVita Inc. Revenue Breakdown – NYSE:DVA - TradingView
DaVita stock holds steady after recent earnings context - AD HOC NEWS
Davita: Valuation Is Nearing Resistance Level (NYSE:DVA) - Seeking Alpha
DaVita stock trades steadily as recent quarterly earnings highlight stable dialysis demand - AD HOC NEWS
DaVita Company Profile & Introduction - Moomoo
DaVita Inc. (DVA) Stock Forecasts - Yahoo! Finance Canada
Moon Capital Management Exited DaVita (DVA) with 174% total Return - Yahoo Finance
DaVita stock trades steadily as dialysis volumes support revenue growth - Ad-hoc-news.de
DaVita Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Summer Heat, Hydration and ESKD: Mitigating Health Risks - DaVita Newsroom
DaVita stock holds on dialysis revenue and margin trends - AD HOC NEWS
DaVita Inc. to announce Q2FY26 results on August 4 - scanx.trade
DaVita schedules Q2 earnings call for August 4, 2026, after market close. - Pluang
DaVita Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call - KITV
What you need to know ahead of DaVita’s earnings release - MSN
DaVita stock trades steady as dialysis operator highlights cash flow and growth investments - AD HOC NEWS
DaVita stock holds firm as earnings and cash flow support dialysis strategy - Ad-hoc-news.de
DaVita stock benefits from expanding community-based kidney care - MSN
DaVita stock trades steadily as dialysis margins and leverage stay in focus - Ad-hoc-news.de
DaVita stock trades steady as chronic kidney care demand supports earnings trajectory - Ad-hoc-news.de
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors - Yahoo Finance
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
DaVita Wins Bid To Decertify 1,300-Member Collective - Law360
DaVita: Why We Exited Our Position In Q2 (DVA) - Seeking Alpha
DaVita gains 21.4% in three months: How should you play the stock? - MSN
DaVita stock trades steadily as kidney care margins and cash flow support valuation - Ad-hoc-news.de
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
DaVita Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DaVita shares more than double after strong Q1 and court win; analyst sells most shares, rates Hold. - Pluang
DaVita: I Believe This Is Overvalued (NYSE:DVA) - Seeking Alpha
What You Need To Know Ahead of DaVita’s Earnings Release - Yahoo Finance
DaVita Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Truist Raises Price Target on DaVita to $250 From $205, Keeps Hold Rating - Moomoo
Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $250 - Moomoo
DaVita expands comprehensive kidney care through dialysis services - MSN
DaVita stock holds steady as kidney care specialist focuses on operations and long-term dialysis dem - ad-hoc-news.de
DaVita Inc. (DVA) Stock Analysis: Strong ROE And Growth Potential In Healthcare Sector - DirectorsTalk Interviews
Exciting News for Farmington: DaVita Maple Valley is Expandi... - Park Hills Daily Journal
DaVita stock reflects steady dialysis demand amid US healthcare focus - ad-hoc-news.de
DVA stock holds steady as dialysis demand underpins the long-term case - ad-hoc-news.de
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why - Yahoo Finance
DaVita Can Return to Long-Term Volume Growth of 2% by 2029, UBS Says - Moomoo
다비타 (DVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
다비타 주식 (DVA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Waters Kathleen Alyce | Chief Legal & Pub. Affairs Off |
Jun 15 '26 |
Sale |
208.40 |
15,405 |
3,210,377 |
109,194 |
| Rodriguez Javier | Chief Executive Officer |
Jun 16 '26 |
Sale |
209.28 |
39,407 |
8,247,018 |
840,408 |
| Rodriguez Javier | Chief Executive Officer |
Jun 15 '26 |
Sale |
209.50 |
30,000 |
6,285,090 |
879,815 |
1.94%
자본화:
|
볼륨(24시간):